CC-4047 in Treating Patients With Myelofibrosis
Completed · Phase 1/Phase 2
Conditions studied: Chronic Myeloproliferative Disorders, Secondary Myelofibrosis
In brief
RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. CC-4047 may also stop the growth of cancer cells by blocking blood flow to the cancer. PURPOSE: This trial is studying the side effects and best dose of CC-4047 and to see how well it works in treating patients with myelofibrosis.
Key facts
- Study ID
- NCT00669578
- Run by
- Mayo Clinic
- People needed
- 77
- Starts
- 2008-05-01
- Expected to finish
- 2019-12-12
- Last updated by the study team
- 2019-12-30
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.